SLC16A1 and metabolic disease: However, to fully elucidate the influence that MCT1 inhibition has on the systemic metabolism and the potential therapeutic benefit of AZD3965 in the context of metabolic disease, additional in vitro and in vivo experiments characterizing changes in adipose tissue morphology and metabolism and systemic metabolism are required.